Tyra biosciences reports second quarter 2023 financial results and highlights

-orphan drug designation granted to tyra-300 for achondroplasia- - surf301 phase 1/2 oncology study remains on target; enrollment ongoing in part b - -tyra-200 phase 1 study on track; first patient to be dosed in 2h 2023- - strong cash position of $232.4 million as of q2 2023- carlsbad, calif. , aug. 10, 2023 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today reported financial results for the quarter ended june 30, 2023 and highlighted recent corporate progress.
TYRA Ratings Summary
TYRA Quant Ranking